| Literature DB >> 23391300 |
Ilker Uçkay1, Hugo Sax, Angèle Gayet-Ageron, Christian Ruef, Kathrin Mühlemann, Nicolas Troillet, Christiane Petignat, Enos Bernasconi, Carlo Balmelli, Andreas Widmer, Karim Boubaker, Didier Pittet.
Abstract
BACKGROUND: Exposure to urinary catheters is considered the most important risk factor for healthcare-associated urinary tract infection (UTI) and is associated with significant morbidity and substantial extra-costs. In this study, we assessed the impact of urinary catheterisation (UC) on symptomatic healthcare-associated UTI among hospitalized patients.Entities:
Year: 2013 PMID: 23391300 PMCID: PMC3598194 DOI: 10.1186/2047-2994-2-5
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Patient characteristics according to the presence of healthcare-associated urinary tract infection (UTI) (n = 8169), Nationwide Prevalence Study, 2004
| | |||
|---|---|---|---|
| Urinary catheter exposure (%) | | | |
| Yes | 73 (57.9) | 1912 (23.8) | |
| No | 53 (42.1) | 6131 (76.2) | |
| Gender, female (%) | 85 (67.5) | 4228 (52.6) | |
| Mean age (±SD) | 71.8 (15.6) | 62.4 (19.0) | |
| Age groups (%) | | | |
| <40 years | 7 (5.7) | 1395 (17.9) | |
| 41-70 years | 37 (30.3) | 3208 (41.2) | |
| > = 71 years | 78 (63.9) | 3184 (40.9) | |
| Hospital size | | | 0.09 |
| <200 acute care beds | 23 (18.3) | 1994 (24.8) | |
| 200-500 beds | 40 (31.8) | 2748 (34.2) | |
| > = 501 beds | 63 (50.0) | 3301 (41.0) | |
| Mean length of stay (±SD) | 20.5(22.2) | 11.4 (41.0) | |
| Length of stay | | | |
| <20 days | 89 (70.6) | 6990 (86.9) | |
| 21-40 days | 22 (17.5) | 677 (8.4) | |
| > = 41 days | 15 (11.9) | 374 (4.7) | |
| Recent stay in intensive care (%) | 34 (27.0) | 1030 (12.8) | |
| Hospitalisation ward (%) | | | |
| Medical ward | 45 (35.7) | 3192 (39.7) | |
| Surgical ward | 50 (39.7) | 3219 (40.0) | |
| Gynaecology/obstetrics | 5 (4.0) | 778 (9.7) | |
| Intensive care unit | 7 (5.6) | 285 (3.5) | |
| Medico-surgical | 19 (15.1) | 569 (7.1) | |
| Recent surgery (%) | 61 (48.4) | 3292 (40.9) | 0.09 |
| Mean ASA score (±SD) | 2.81 (0.67) | 2.33 (0.89) | |
| ASA (%) | | | |
| 1 pt | 4 (3.2) | 1587 (19.8) | |
| 2-3 pts | 109 (87.2) | 5802 (72.3) | |
| 4-5 pts | 12 (9.6) | 634 (7.9) | |
| McCabe/Jackson (%) | | | |
| Non fatal | 82 (65.1) | 6143 (76.4) | |
| Fatal within 5 years | 36 (28.6) | 1455 (18.1) | |
| Fatal within 6 months | 8 (6.4) | 445 (5.5) | |
| Mean nursing workload (±SD) | 204.0 (161.4) | 168.3 (162.8) | |
| Mean Charlson index (±SD) | 1.8 (2.1) | 1.2 (1.8) | |
| Charlson group (%) | | | |
| 0-3 pts | 106 (84.1) | 7267 (90.4) | |
| > = 4 pts | 20 (15.9) | 776 (9.7) | |
| Co-morbidities (%) | | | |
| Diabetes mellitus | 19 (15.1) | 1074 (13.4) | 0.57 |
| Immune suppression° | 26 (20.6) | 1047 (13.0) | |
| Hemiplegia | 24 (19.1) | 777 (9.7) | |
| Dementia | 9 (7.1) | 290 (3.6) |
ASA, American Society of Anesthesiologists; (%) = proportion of all surveyed patients according to number of the variable of interest among the study population; SD = standard deviation; °autoimmune disease, transplantation, hepatopathy, nephropathy, neoplasia.
Multivariate logistic regression models clustered on hospitals presenting independent factors associated with urinary tract infection stratified on prior exposure to urinary catheter, Nationwide Prevalence Study, 2004
| Age groups (%) | | | 0.62 | | | |
| <40 years | 1.00 | - | - | 1.00 | - | - |
| 41-70 years | 1.77 | 0.51-6.10 | 0.36 | 1.03 | 0.31-3.45 | 0.96 |
| > = 71 years | 1.84 | 0.54-6.26 | 0.33 | 2.53 | 0.81-7.94 | 0.11 |
| Recent surgical intervention | | | 0.75 | | | 0.59 |
| No | 1.00 | - | | 1.00 | - | |
| Yes | 0.92 | 0.54-1.56 | | 0.84 | 0.44-1.59 | |
| ASA score (%) | | | | | 0.39 | |
| 1 pt | 1.00 | - | - | 1.00 | - | - |
| 2-3 pts | 7.21 | 0.96-54.35 | 0.06 | 1.99 | 0.54-7.28 | 0.30 |
| 4-5 pts | 4.52 | 0.51-39.74 | 0.17 | 1.11 | 0.18-6.78 | 0.91 |
| Charlson group | | | 0.55 | | | 0.76 |
| 0-3 pts | 1.00 | - | | 1.00 | - | |
| > = 4 pts | 1.30 | 0.55-3.08 | | 0.85 | 0.30-2.40 | |
| Length of stay | | | | | ||
| <20 days | 1.00 | - | - | 1.00 | - | - |
| 21-40 days | 1.88 | 0.92-3.85 | 0.08 | 2.01 | 0.95-4.22 | 0.07 |
| > = 41 days | 2.87 | 1.34-6.11 | 0.006 | 2.12 | 0.84-5.35 | 0.11 |
| Recent stay in intensive care | | | 0.99 | | | |
| No | 1.00 | - | | 1.00 | - | |
| Yes | 1.00 | 0.58-1.73 | | 2.30 | 1.01-5.20 | |
| McCabe/Jackson (%) | | | 0.95 | | | 0.18 |
| Non fatal | 1.00 | - | - | 1.00 | - | - |
| Fatal within 5 years | 0.98 | 0.54-1.77 | 0.95 | 1.71 | 0.88-3.31 | 0.11 |
| Fatal within 6 months | 1.15 | 0.45-2.93 | 0.76 | 0.50 | 0.06-3.87 | 0.50 |
| Gender | | | | | ||
| Male | 1.00 | - | | 1.00 | - | |
| Female | 1.61 | 0.98-2.65 | | 3.27 | 1.65-6.48 | |
| Hemiplegia | | | 0.78 | | | |
| No | 1.00 | - | | 1.00 | - | |
| Yes | 1.10 | 0.55-2.20 | | 2.10 | 1.07-4.11 | |
| Immune suppression° | | | 0.67 | | | 0.45 |
| No | 1.00 | - | | 1.00 | - | |
| Yes | 1.18 | 0.54-2.58 | 1.42 | 0.57-3.51 | ||
*Independent variables significantly (or slightly significantly) associated with urinary tract infection.
ASA = American Society of Anesthesiologists; autoimmune disease, transplantation, hepatopathy, nephropathy, neoplasia.
Multivariate logistic regression models clustered on hospitals presenting independent factors associated with urinary tract infection stratified on gender, Nationwide Prevalence Study, 2004
| Age groups (%) | | | | | ||
| <70 years | 1.00 | - | | 1.00 | - | - |
| > = 71 years | 2.57 | 1.24-5.31 | | 1.51 | 0.93-2.45 | |
| Recent surgical intervention | | | 0.78 | | | 0.43 |
| No | 1.00 | - | | 1.00 | - | |
| Yes | 1.11 | 0.55-2.21 | | 0.82 | 0.49-1.35 | |
| ASA score (%) | | | 0.30 | | | 0.47 |
| <4 pts | 1.00 | - | | 1.00 | - | - |
| 4-5 pts | 0.52 | 0.15-1.81 | | 0.73 | 0.31-1.73 | |
| Charlson group | | | 0.50 | | | 0.89 |
| 0-3 pts | 1.00 | - | | 1.00 | - | |
| > = 4 pts | 1.44 | 0.50-4.11 | | 0.94 | 0.39-2.28 | |
| Length of stay | | | 0.57 | | | |
| <20 days | 1.00 | - | - | 1.00 | - | - |
| 21-40 days | 0.86 | 0.26-2.92 | 0.81 | 2.75 | 1.52-4.96 | 0.001 |
| > = 41 days | 1.75 | 0.59-5.17 | 0.31 | 2.89 | 1.41-5.92 | 0.004 |
| Recent stay in intensive care | | | 0.59 | | | |
| No | 1.00 | - | | 1.00 | - | |
| Yes | 0.79 | 0.35-1.81 | | 1.83 | 1.03-3.24 | |
| McCabe classification (%) | | | 0.84 | | | |
| Non fatal | 1.00 | - | - | 1.00 | - | - |
| Fatal within 5 years | 0.81 | 0.36-1.82 | 0.61 | 1.70 | 0.99-2.91 | 0.05 |
| Fatal within 6 months | 1.11 | 0.31-4.04 | 0.87 | 0.98 | 0.32-3.00 | 0.98 |
| Prior exposure to urinary catheter | | | | | ||
| No | 1.00 | - | | 1.00 | - | |
| Yes | 6.77 | 3.20-14.35 | | 3.04 | 1.83-5.04 | |
| Hemiplegia | | | | | 0.34 | |
| No | 1.00 | - | | 1.00 | - | |
| Yes | 2.04 | 0.93-4.46 | | 1.36 | 0.73-2.54 | |
| Immune suppression° | | | 0.39 | | | 0.57 |
| No | 1.00 | - | | 1.00 | - | |
| Yes | 1.55 | 0.57-4.18 | 1.24 | 0.58-2.65 | ||
*Independent variables significantly (or slightly significantly) associated with urinary tract infection.
ASA American Society of Anesthesiologists; autoimmune disease, transplantation, hepatopathy, nephropathy, neoplasia.
Prevalence of urinary catheter use and/or symptomatic healthcare-associated urinary tract infection: reports in the peer-reviewed literature (January 1980-December 2012)
| Jepsen et al.
[ | 40 hospitals in eight countries, n = 3899 | Point prevalence | 10.1% men, 11.8% women | 6.5% | Conducted in 1980 |
| Moro et al.
[ | 130 hospitals, n = 34,577 | Point prevalence | 9.4% | 2.1% | National prevalence survey in Italy, 1983 |
| Mertens et al.
[ | 106 hospitals, n = 8723 | Point prevalence | 15.7% | 4.4% | National prevalence survey in Belgium 1984 70% surgery. Definition nosocomial: > 3rd day |
| Srámova et al.
[ | 23 hospitals, n = 12,260 | Point prevalence | | 1.5% | Prevalence survey in Czechoslovakia, 1984 |
| Emmerson et al.
[ | 157 centres, n = 37,111 | Survey | - | 2.4% | Prevalence survey in UK and Ireland, 1994 |
| Gastmeier et al.
[ | 72 hospitals, n = 14,966 | Point prevalence | | 1.1% | National prevalence survey in Germany, 1994 |
| Scheel et al.
[ | All acute care hospitals, n = 12,755 | Point prevalence | - | 2.2% | National prevalence survey in Norway, 1997 |
| Vaqué et al.
[ | n = 51,674 in 1997 | Point prevalence | - | 2.1% | National prevalence surveys in Spain, 1990-1997 |
| French Prevalence Group
[ | 830 hospitals, n = 236,334 | Point prevalence | 9.6% | 1.6% | National prevalence survey in France, 1996, including psychiatric and long-term care wards |
| Eriksen et al.
[ | Acute care hospitals, n = 11,500-12,500 | Point prevalence | - | 1.7-2.0% | National prevalence surveys in Norway, |
| Gikas et al.
[ | n = 3925 | Point prevalence | 8.6% | 2.1% | Survey in 14 Greek hospitals, 1999 |
| Lizioli et al.
[ | Public hospitals, n = 18,667 | Point prevalence | - | 1.6% | Prevalence survey in Lombardy, 2000 |
| Klavs et al.
[ | Acute care, n = 6695 | Point prevalence | - | 1.2% | National prevalence survey in Slovenia, 2001 |
| Nicastri et al.
[ | 15 hospitals in Italy, n = 2165 | Point prevalence | 22.4% | 1.7% | All participating hospitals have > 400 beds |
| Wald et al.
[ | Surgery, n = 111,330 523 Medicare hospitals | Retrospective cohort study | 32% at discharge day | - | Patients at discharge after hip replacement |
| Tammelin
[ | 31 hospitals, n = 6369 | | 16.5% | 1.65% | Acute hospitals and long-term care facilities in Sweden, 2002 |
| Gravel et al.
[ | n = 5750 | Point prevalence | 22% | 3.4% | National prevalence survey in Canada, 2002 |
| Hopmans et al.
[ | 2 tertiary Dutch hospitals, n = 2661 | Point prevalence twice a year | - | 2.3% (1.2%-3.4%) | 2001-2004. Obstetric wards excluded |
| Kevens et al.
[ | 445 US hospitals, n = 33,726,611 | Throughout the year 2002 | - | 1.3% | Estimations for the USA |
| Pelizzer et al.
[ | 21 Italian hospitals, n = 6352 | Period prevalence | 25.2% | 2.2% | Prevalence study in Veneto region, Italy 2003 |
| van den Broek et al.
[ | 10 hospitals, n = 16,495 | Period prevalence | 20.2% | 2.6% | Netherlands, acute care hospitals |
| Cairns et al.
[ | 45 acute care hospitals, n = 11,090 | Point prevalence | 20.3% | 2.0% | Scotland 2006, exclusion of obstetric patients |
| Cotter et al.
[ | 69 long-term care facilities, n = 4,170 | Point prevalence | 5.6% | 1.5% | Long-term care facilities in Ireland, June 2010 |
| Askarian et al.
[ | 8 university hospitals, n = 3450 | Point prevalence | 23.1% | 1.4% | University hospitals in Shiraz, Iran |
| Health Protection Agency
[ | 103 healthcare facilities, n = 52,443 | Point prevalence | 18.8% | 1.1% | English national point prevalence survey preliminary data |
| Acute care hospitals, n = 8169 | Period prevalence Cluster-adapted | 24% | 1.5% | National prevalence survey in Switzerland, 2004 |
* Only reports including at least 2000 patients admitted to acute care facilities are included.